IDEAS home Printed from https://ideas.repec.org/a/spr/pharme/v39y2021i12d10.1007_s40273-021-01073-y.html
   My bibliography  Save this article

Early Cost Effectiveness of Whole-Genome Sequencing as a Clinical Diagnostic Test for Patients with Inoperable Stage IIIB,C/IV Non-squamous Non-small-Cell Lung Cancer

Author

Listed:
  • Martijn J. H. G. Simons

    (Maastricht University Medical Centre
    Maastricht University, Care and Public Health Research Institute (CAPHRI))

  • Valesca P. Retèl

    (Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital
    University of Twente)

  • Bram L. T. Ramaekers

    (Maastricht University Medical Centre
    Maastricht University, Care and Public Health Research Institute (CAPHRI))

  • Rogier Butter

    (Amsterdam University Medical Center, University of Amsterdam)

  • Joanne M. Mankor

    (Erasmus Medical Centre)

  • Marthe S. Paats

    (Erasmus Medical Centre)

  • Joachim G. J. V. Aerts

    (Erasmus Medical Centre)

  • Zakile A. Mfumbilwa

    (Amsterdam University Medical Center-Location VUmc)

  • Paul Roepman

    (Hartwig Medical Foundation)

  • Veerle M. H. Coupé

    (Amsterdam University Medical Center-Location VUmc)

  • Carin A. Uyl-de Groot

    (Erasmus University Rotterdam)

  • Wim H. van Harten

    (Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital
    University of Twente)

  • Manuela A. Joore

    (Maastricht University Medical Centre
    Maastricht University, Care and Public Health Research Institute (CAPHRI))

Abstract

Background Advanced non-small-cell lung cancer (NSCLC) harbours many genetic aberrations that can be targeted with systemic treatments. Whole-genome sequencing (WGS) can simultaneously detect these (and possibly new) molecular targets. However, the exact added clinical value of WGS is unknown. Objective The objective of this study was to determine the early cost effectiveness of using WGS in diagnostic strategies compared with currently used molecular diagnostics for patients with inoperable stage IIIB,C/IV non-squamous NSCLC from a Dutch healthcare perspective. Methods A decision tree represented the diagnostic pathway, and a cohort state transition model represented disease progression. Three diagnostic strategies were modelled: standard of care (SoC) alone, WGS as a diagnostic test, and SoC followed by WGS. Treatment effectiveness was based on a systematic review. Probabilistic cost-effectiveness analyses were performed, and threshold analyses (using €80,000 per quality-adjusted life-year [QALY]) was used to explore the early cost effectiveness of WGS. Results WGS as a diagnostic test resulted in more QALYs (0.002) and costs (€1534 [incremental net monetary benefit –€1349]), and SoC followed by WGS resulted in fewer QALYs (–0.002) and more costs (€1059 [–€1194]) compared with SoC alone. WGS as a diagnostic test was only cost effective if it was priced at €2000 per patient and identified 2.7% more actionable patients than SoC alone. Treating these additional identified patients with new treatments costing >€4069 per month decreased the probability of cost effectiveness. Conclusions Our analysis suggests that providing WGS as a diagnostic test is cost effective compared with SoC followed by WGS and SoC alone if costs for WGS decrease and additional patients with actionable targets are identified. This cost-effectiveness model can be used to incorporate new findings iteratively and to support ongoing decision making regarding the use of WGS in this rapidly evolving field.

Suggested Citation

  • Martijn J. H. G. Simons & Valesca P. Retèl & Bram L. T. Ramaekers & Rogier Butter & Joanne M. Mankor & Marthe S. Paats & Joachim G. J. V. Aerts & Zakile A. Mfumbilwa & Paul Roepman & Veerle M. H. Coup, 2021. "Early Cost Effectiveness of Whole-Genome Sequencing as a Clinical Diagnostic Test for Patients with Inoperable Stage IIIB,C/IV Non-squamous Non-small-Cell Lung Cancer," PharmacoEconomics, Springer, vol. 39(12), pages 1429-1442, December.
  • Handle: RePEc:spr:pharme:v:39:y:2021:i:12:d:10.1007_s40273-021-01073-y
    DOI: 10.1007/s40273-021-01073-y
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s40273-021-01073-y
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.

    File URL: https://libkey.io/10.1007/s40273-021-01073-y?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Nurchis, Mario Cesare & Riccardi, Maria Teresa & Radio, Francesca Clementina & Chillemi, Giovanni & Bertini, Enrico Silvio & Tartaglia, Marco & Cicchetti, Americo & Dallapiccola, Bruno & Damiani, Gian, 2022. "Incremental net benefit of whole genome sequencing for newborns and children with suspected genetic disorders: Systematic review and meta-analysis of cost-effectiveness evidence," Health Policy, Elsevier, vol. 126(4), pages 337-345.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharme:v:39:y:2021:i:12:d:10.1007_s40273-021-01073-y. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.